# Can You Take a GLP-1 With Epilepsy? Seizure Risk Did Not Rise | This GLP Can you take a GLP-1 with epilepsy? A 452,766-adult cohort found incident epilepsy at 2.35% against 2.41%, a hazard ratio of 0.84, and no trial in people who already have it. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/can-you-take-a-glp1-with-epilepsy Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Can You Take a GLP-1 With Epilepsy? Seizure Risk Did Not Rise A 452,766-person study found a clean, consistent association. Expressed as people rather than ratios, it is one case avoided per sixteen hundred treated. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min read Cumulative epilepsy incidence · 2.35% · on a GLP-1 · 2.41% · on a DPP-4 drug · Reported as: 16% lower risk (HR 0.84). · Actual gap: 0.06 percentage points. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). Nothing in this evidence says you cannot, and nothing says the drug will help the epilepsy. A matched cohort of 452,766 adults with type 2 diabetes recorded incident epilepsy in 2.35% of GLP-1 users against 2.41% of DPP-4 comparators [\[1\]](https://thisglp.com/research/can-you-take-a-glp1-with-epilepsy#ref-1). That is a hazard ratio of 0.84 (95% CI 0.78 to 0.90). The 16% relative reduction is an absolute difference of 0.06 percentage points, or roughly one case avoided per sixteen hundred people treated. Everyone in it was free of epilepsy at baseline, so it is a question about developing the condition rather than living with it. No trial has tested one of these drugs in people who already have it. ## Key takeaways - A matched cohort of 452,766 adults with type 2 diabetes compared new users of GLP-1 drugs against DPP-4 inhibitors for incident epilepsy. - Epilepsy developed in 1,670 GLP-1 users and 1,886 comparators — cumulative incidences of 2.35% and 2.41%. - The hazard ratio was 0.84 (95% CI 0.78-0.90), holding at one, three and five years and across age and sex subgroups. - A 16% relative reduction on those incidences is an absolute difference of 0.06 percentage points. This is a well-conducted study whose headline is nearly meaningless to an individual [\[1\]](https://thisglp.com/research/can-you-take-a-glp1-with-epilepsy#ref-1). It is the clearest example on this site of why both numbers must be printed. The general problem is set out in [the semaglutide and tirzepatide comparison](https://thisglp.com/research/bigger-relative-smaller-absolute). Across 452,766 matched patients, epilepsy developed in 1,670 people on a GLP-1 drug and 1,886 on a DPP-4 inhibitor. That is 2.35% against 2.41%. The hazard ratio of 0.84 (95% CI 0.78–0.90) accounts for follow-up time and is correctly calculated; it will be reported as a 16% reduction in epilepsy risk. Six hundredths of a percentage point The two cumulative incidences differ by 0.06 points. Expressed as people, that is roughly one case of epilepsy avoided for every sixteen hundred patients treated — set against a hazard ratio that sounds like a substantial protective effect. Neither figure is wrong. A reader deciding whether epilepsy risk should influence their choice of diabetes drug needs the second one, and will almost certainly be shown the first. The quality of the study and the size of its finding are separate judgments and should not be collapsed. This one is large, and the associations held at one, three and five years. They were consistent across age and sex, and sensitivity analyses supported them, comparable rigor to [the venous thromboembolism cohort](https://thisglp.com/research/do-glp1-drugs-cause-blood-clots). Semaglutide showed the strongest association at a hazard ratio of 0.68. That rests on the same near-identical incidences, so it is a larger relative figure attached to the same tiny absolute one. Whether there is a mechanism is genuinely open. Epilepsy and metabolic disease share pathways that these drugs plausibly touch. This is not the first neurological association to appear in observational data while trial evidence stays quiet. The same pattern is described in [lower odds of getting Parkinson's, no help once you have it](https://thisglp.com/research/preventing-it-is-not-treating-it), where prevention signals and treatment nulls came from different study designs. ## Where the rest of the neurological evidence sits Two larger poolings frame this one. A systematic review screened 10,037 records and pooled 82 studies of neuropsychiatric outcomes, graded with GRADE [\[2\]](https://thisglp.com/research/can-you-take-a-glp1-with-epilepsy#ref-2). Risk of developing Parkinson’s disease was lower at a pooled hazard ratio of 0.70, 95% CI 0.53 to 0.92, from observational data. Motor symptoms in people who already had it did not improve, mean difference −3.29, 95% CI −7.84 to 1.26, from trials. A Bayesian network meta-analysis of 712,287 patients found no antidiabetic class with a significant difference in Parkinson’s risk [\[3\]](https://thisglp.com/research/can-you-take-a-glp1-with-epilepsy#ref-3). Its own conclusion nonetheless describes GLP-1 and SGLT2 drugs as consistently associated with lower risk. The gap between a paper’s results and its conclusion is set out in [the Parkinson's evidence](https://thisglp.com/research/do-glp1-drugs-help-parkinsons-disease). The practical translation is short. Nobody should choose or avoid a diabetes drug on epilepsy grounds from this evidence, and nobody with epilepsy should expect a GLP-1 drug to do anything for it. What the study contributes is a reassurance: these drugs do not appear to raise seizure risk. That is useful to have measured at this scale, in the same way the respiratory null in [the respiratory adverse event review](https://thisglp.com/research/one-asthma-study-in-a-hundred-and-twenty-three) is useful. ## Frequently asked Can you take a GLP-1 if you have epilepsy? No study has tested one in people who already have epilepsy. The largest cohort available enrolled 452,766 adults free of it at baseline and found incident epilepsy at 2.35% against 2.41%, which is reassurance about seizure risk rather than evidence of a treatment effect. Do these drugs reduce epilepsy risk? The association is real and consistent, but tiny in absolute terms: 2.35% against 2.41%, or roughly one case avoided per sixteen hundred people treated. Why does the 16% figure sound so much larger? A hazard ratio expresses a proportional change. Sixteen percent of a 2.4% risk is a very small number of people, which is why absolute figures matter for any personal decision. Should this affect my choice of diabetes drug? No. The difference is too small to weigh against efficacy, tolerability or cost. Its value is as reassurance that these drugs do not appear to increase seizure risk. ## Sources 1. \[1\] Cheng CY, Lo SC, Huang CN, Yang YS, Wang YH, Kornelius E (2026). Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes Neurology. [PMID 41370744](https://pubmed.ncbi.nlm.nih.gov/41370744/) 2. \[2\] Choudhury I, Ward JH, Mahesh S, Alam U, Azmi S, Anson M (2026). Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis Clinical Therapeutics. [PMID 41862354](https://pubmed.ncbi.nlm.nih.gov/41862354/) 3. \[3\] Lee SH, et al. (2026). Comparative neuroprotective effects of antidiabetic medications on Parkinson's disease risk: a Bayesian network meta-analysis Journal of Global Health. [PMID 42626880](https://pubmed.ncbi.nlm.nih.gov/42626880/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)